|
| Wednesday, October 4, 2023 |
|
|
Eisai: Notice of Absorption-Type Merger (Simplified Merger/Short-Form Merger) of KAN Research Institute, Inc. |
| Eisai Co., Ltd. hereby announcesthat the Company has today decided to absorb and merge with KAN Research Institute, Inc., the Company's wholly owned subsidiary on April 1, 2024. more info >> |
|
| Thursday, September 28, 2023 |
|
|
Eisai Launches New "Innovation" Page on Corporate Website |
| Eisai Co., Ltd. announced today that it has launched a new "Innovation" page on its corporate website. more info >> |
|
|
Tokio Marine Nichido and Eisai Co-Develop Industry's First "Dementia Care Support Insurance" |
| Tokio Marine & Nichido Fire Insurance Co., Ltd. and Eisai Co., Ltd. announced that they have co-developed "Dementia Care Support Insurance" to financially support early detection and early treatment for dementia as a part of their business alliance for the realization of a Dementia Inclusive Society. more info >> |
|
| Monday, September 25, 2023 |
|
|
"LEQEMBI Intravenous Infusion" (Lecanemab) Approved for the Treatment of Alzheimer's Disease in Japan |
| Eisai Co., Ltd. and Biogen Inc. announced today that humanized anti- soluble aggregated amyloid-beta (Abeta) monoclonal antibody "LEQEMBI" Intravenous Infusion (200 mg, 500mg, lecanemab) has been approved in Japan as a treatment for slowing progression of mild cognitive impairment (MCI) and mild dementia due to Alzheimer's disease (AD). more info >> |
|
| Thursday, September 21, 2023 |
|
|
Eisai: Release of Dementia Disease Awareness Videos for World Alzheimer's Day, September 21 |
| Eisai Co., Ltd. announced today on World Alzheimer's Day, that it has released a dementia awareness video, "Life Goes On 2023: Two Memories, One Story", on its dementia information website "Sodan.e-65" and YouTube, which are intended to deepen the understanding of dementia. more info >> |
|
| Tuesday, September 12, 2023 |
|
|
Eisai Establishes Theoria Technologies Co., Ltd., A New Digital Business Company To Build A Dementia Ecosystem |
| Eisai Co., Ltd. announced today that it has established a digital business company Theoria technologies Co., Ltd. ("Theoria technologies") which will accelerate the development of a dementia ecosystem. Theoria technologies is a wholly owned subsidiary of Eisai. more info >> |
|
| Friday, August 4, 2023 |
|
|
エーザイ、社会的責任投資指数「FTSE4Good Index Series」の構成銘柄に22年連続で選定 |
| エーザイ株式会社（本社：東京都、代表執行役CEO：内藤晴夫）は、このたび、社会的責任投資の代表的な指数である「FTSE4Good Index Series」の構成銘柄に、2002年以来22年連続で選定されたことをお知らせします。 more info >> |
|
|
Eisai Listed for 22nd Consectutive Year In FTSE4Good Index Series, An Index for Socially Responsible Investment |
| Eisai Co., Ltd. announced today that it has been included in the FTSE4Good Index Series for the 22nd consecutive year since its initial inclusion in 2002. more info >> |
|
| Thursday, July 20, 2023 |
|
|
エーザイ、「レカネマブ」について、アルツハイマー病の病理に対する効果、および皮下投与に関する最新の解析結果をアルツハイマー病協会国際会議2023（AAIC2023）において発表 |
| エーザイ株式会社とバイオジェン・インクは、このたび、アルツハイマー病（AD）治療剤レカネマブ（一般名、米国ブランド名：「LEQEMBI」）について、臨床第III相Clarity AD試験におけるレカネマブ投与によるアミロイドベータ（Aβ）の減少とパスウェイにおける下流のバイオマーカー変化の解析結果、ならびに現在開発中の皮下投与製剤に関する最新知見をアルツハイマー病協会国際会議2023において、発表したことをお知らせします。 more info >> |
|
|
Eisai Presents Latest Analysis of Lecanemab's Effect on Biomarker Changes and Subcutaneous Dosing at The Alzheimer's Association International Conference (AAIC) 2023 |
| Eisai Co., Ltd. and Biogen Inc. announced today that the results of a detailed analysis of the Phase 3 Clarity AD study demonstrated that lecanemab-irmb (generic name, U.S. brand name: LEQEMBI) treatment showed reductions in amyloid-beta (Abeta) pathology and downstream biomarker changes. more info >> |
|
|
|
|
